{"id":"tace-plus-sorafenib","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Hand-foot skin reaction"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Hypertension"},{"rate":"variable","effect":"Hepatic dysfunction"},{"rate":"40-60","effect":"Post-embolization syndrome (fever, pain, nausea)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TACE is a locoregional procedure that embolizes the hepatic artery feeding the tumor while delivering chemotherapy directly to the lesion. Sorafenib is a multi-kinase inhibitor targeting VEGFR, PDGFR, RAF, and FLT3, which blocks tumor angiogenesis and proliferation. The combination aims to enhance local tumor control via TACE while systemic sorafenib prevents residual disease and metastatic progression.","oneSentence":"TACE (transarterial chemoembolization) combined with sorafenib delivers chemotherapy directly to liver tumors while sorafenib inhibits multiple tyrosine kinases to suppress tumor angiogenesis and growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:55.379Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (HCC), intermediate to advanced stage"}]},"trialDetails":[{"nctId":"NCT07449065","phase":"","title":"CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI)","enrollment":324},{"nctId":"NCT01906216","phase":"PHASE3","title":"Sorafenib Chemoembolization Evaluation Controlled Trial","status":"COMPLETED","sponsor":"Air Force Military Medical University, China","startDate":"2013-09","conditions":"Hepatocellular Carcinoma","enrollment":199},{"nctId":"NCT02856126","phase":"PHASE3","title":"HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-08","conditions":"Hepatocellular Carcinoma","enrollment":214},{"nctId":"NCT04518852","phase":"PHASE2","title":"TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC","status":"COMPLETED","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2020-09-14","conditions":"Hepatocellular Carcinoma, Liver Neoplasms, Digestive System Neoplasms","enrollment":27},{"nctId":"NCT05717738","phase":"","title":"Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-01-20","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT04103398","phase":"PHASE3","title":"TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2019-10-02","conditions":"Hepatocellular Carcinoma, Sorafenib, Transarterial Chemoembolization","enrollment":162},{"nctId":"NCT06261138","phase":"","title":"Survival Analysis: TACE vs. Combination Therapy in HCC","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":279},{"nctId":"NCT06205732","phase":"","title":"A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2024-01-01","conditions":"Carcinoma, Hepatocellular","enrollment":100},{"nctId":"NCT01004978","phase":"PHASE3","title":"Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-28","conditions":"Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma","enrollment":235},{"nctId":"NCT06177496","phase":"","title":"Influence of Sarcopenia in Hepatocellular Carcinoma Patients","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2024-02-01","conditions":"Sarcopenia","enrollment":600},{"nctId":"NCT03722498","phase":"PHASE2","title":"Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT04992143","phase":"PHASE2","title":"TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-08-20","conditions":"BCLC Stage C Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT04387695","phase":"PHASE3","title":"SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-04-30","conditions":"Unresectable Hepatocellular Carcinoma, Portal Vein Thrombosis","enrollment":54},{"nctId":"NCT05332496","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT05332821","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":474},{"nctId":"NCT04599777","phase":"PHASE2","title":"TACE Combined With Sorafenib and Tislelizumab for Advanced HCC","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2020-10-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":30},{"nctId":"NCT05535998","phase":"","title":"TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT","status":"COMPLETED","sponsor":"Yunfei Yuan","startDate":"2021-01-01","conditions":"Hepatocellular Carcinoma","enrollment":743},{"nctId":"NCT05420922","phase":"","title":"Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2021-11-01","conditions":"Hepatocellular Carcinoma, Programmed Cell Death 1, Effects of Immunotherapy","enrollment":2000},{"nctId":"NCT02794337","phase":"PHASE2, PHASE3","title":"TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer","status":"UNKNOWN","sponsor":"Tata Memorial Hospital","startDate":"2014-12","conditions":"Carcinoma, Hepatocellular","enrollment":67},{"nctId":"NCT05121571","phase":"NA","title":"The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-04-21","conditions":"Hepatocellular Carcinoma","enrollment":114},{"nctId":"NCT05135364","phase":"PHASE2","title":"HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure","status":"UNKNOWN","sponsor":"Yue Han","startDate":"2021-11-05","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":48},{"nctId":"NCT00844883","phase":"PHASE2","title":"Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Yale University","startDate":"2009-02","conditions":"Hepatocellular Carcinoma, Hepatoma","enrollment":50},{"nctId":"NCT04127396","phase":"PHASE4","title":"Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2019-09-01","conditions":"Carcinoma, Hepatocellular, Portal Vein Tumor Thrombus","enrollment":72},{"nctId":"NCT04926532","phase":"PHASE1, PHASE2","title":"Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2019-08-01","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT02460991","phase":"PHASE3","title":"A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Boston Scientific Corporation","startDate":"2015-11","conditions":"Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma","enrollment":2},{"nctId":"NCT04229355","phase":"PHASE3","title":"DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2021-02-02","conditions":"Hepatocellular Carcinoma","enrollment":90},{"nctId":"NCT04479527","phase":"PHASE2","title":"Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-04","conditions":"Hepatocellular Carcinoma","enrollment":34},{"nctId":"NCT01714609","phase":"PHASE2","title":"The Effect of Sorafenib on Portal Pressure","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-08","conditions":"Clinically Significant Portal Hypertension","enrollment":10},{"nctId":"NCT04317248","phase":"PHASE2","title":"\"Cocktail\" Therapy for Hepatitis B Related Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Yuehua Huang","startDate":"2020-04-01","conditions":"Hepatocellular Carcinoma","enrollment":600},{"nctId":"NCT04143191","phase":"PHASE3","title":"Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-09-15","conditions":"Hepatocellular Carcinoma","enrollment":158},{"nctId":"NCT01833299","phase":"PHASE3","title":"Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2010-01","conditions":"Hepatocellular Carcinoma, Face Cancer","enrollment":120},{"nctId":"NCT02504983","phase":"PHASE4","title":"Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2015-08","conditions":"Hepatocellular Carcinoma","enrollment":200},{"nctId":"NCT02436902","phase":"PHASE3","title":"Adjuvant Therapies for Patients With HCC and MVI","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":240},{"nctId":"NCT00825955","phase":"PHASE3","title":"Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-02-17","conditions":"Liver Cancer","enrollment":587},{"nctId":"NCT02529761","phase":"NA","title":"TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2015-08","conditions":"Hepatocellular Carcinoma","enrollment":330},{"nctId":"NCT02372162","phase":"","title":"Fingerprint Characterization of Advanced HCC","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2015-07","conditions":"Carcinoma, Hepatocellular","enrollment":25},{"nctId":"NCT02220088","phase":"PHASE2, PHASE3","title":"The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2014-12","conditions":"Hepatocellular Carcinoma","enrollment":79},{"nctId":"NCT03730675","phase":"NA","title":"Irradiation Stent Placement Plus TACE for HCC and PVTT","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2018-11-10","conditions":"Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis","enrollment":308},{"nctId":"NCT01933945","phase":"","title":"Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-10-28","conditions":"Carcinoma, Hepatocellular","enrollment":1676},{"nctId":"NCT01409499","phase":"PHASE4","title":"Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-01","conditions":"Hepatectomy, Hepatocellular Carcinoma, Sorafenib","enrollment":180},{"nctId":"NCT03518502","phase":"PHASE4","title":"Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis","status":"UNKNOWN","sponsor":"Korea University","startDate":"2012-03-01","conditions":"Hepatocellular Carcinoma, Metastasis","enrollment":130},{"nctId":"NCT01829035","phase":"PHASE3","title":"A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2013-02-21","conditions":"Advanced Adult Hepatocellular Carcinoma","enrollment":339},{"nctId":"NCT02908165","phase":"PHASE2","title":"Randomized Phase II Trial of Chemoembolization and Sorafenib","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2016-06","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT01011010","phase":"PHASE1","title":"Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2009-07-22","conditions":"Liver Cancer","enrollment":11},{"nctId":"NCT01839630","phase":"","title":"Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-05-30","conditions":"Carcinoma, Hepatocellular","enrollment":302},{"nctId":"NCT02311205","phase":"PHASE2","title":"Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2014-12","conditions":"Hepatocellular Carcinoma, Metastasis","enrollment":55},{"nctId":"NCT03338166","phase":"","title":"Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-01-02","conditions":"Hepatocellular Carcinoma","enrollment":50},{"nctId":"NCT01217034","phase":"PHASE2","title":"Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib","status":"UNKNOWN","sponsor":"Kindai University","startDate":"2010-10","conditions":"Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Carcinoma, Hepatocellular","enrollment":228},{"nctId":"NCT02616692","phase":"","title":"HCC Patient Preferences in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-05-09","conditions":"Hepatocellular Cancer","enrollment":120},{"nctId":"NCT01901692","phase":"PHASE2, PHASE3","title":"Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2013-07-29","conditions":"Hepatocellular Carcinoma","enrollment":90},{"nctId":"NCT00855218","phase":"PHASE2","title":"A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-03","conditions":"Carcinoma, Hepatocellular","enrollment":307},{"nctId":"NCT01507064","phase":"PHASE2","title":"Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Cardarelli Hospital","startDate":"2012-01","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT00576056","phase":"PHASE2","title":"Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC","status":"TERMINATED","sponsor":"University of Pittsburgh","startDate":"2008-01","conditions":"Carcinoma, Hepatocellular","enrollment":19},{"nctId":"NCT01480817","phase":"PHASE2","title":"Sorafenib VS TACE in HCC Patients With Portal Vein Invasion","status":"TERMINATED","sponsor":"Seoul National University Hospital","startDate":"2012-06","conditions":"Hepatocellular Carcinoma","enrollment":2},{"nctId":"NCT02150317","phase":"NA","title":"Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2014-01","conditions":"Advanced Hepatocellular Carcinoma","enrollment":180},{"nctId":"NCT01539018","phase":"PHASE2","title":"Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE","status":"TERMINATED","sponsor":"Egyptian Society of Liver Cancer","startDate":"2012-01","conditions":"Advanced Hepatocellular Carcinoma","enrollment":77},{"nctId":"NCT00494299","phase":"PHASE3","title":"Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-04","conditions":"Carcinoma, Hepatocellular","enrollment":458},{"nctId":"NCT01618253","phase":"PHASE1","title":"Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2012-06","conditions":"Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatoma","enrollment":""},{"nctId":"NCT01042041","phase":"PHASE1","title":"Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2009-09","conditions":"Hepatocellular Carcinoma, Liver Cancer, Localized Unresectable Liver Cancer","enrollment":18},{"nctId":"NCT00618384","phase":"PHASE2","title":"TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2008-01","conditions":"Hepatocellular Carcinoma","enrollment":43},{"nctId":"NCT00919009","phase":"PHASE2","title":"Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2009-06","conditions":"Carcinoma, Hepatocellular","enrollment":50},{"nctId":"NCT01605734","phase":"PHASE2","title":"TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2012-07","conditions":"PHENYTOIN/SORAFENIB [VA Drug Interaction], Carcinoma, Hepatocellular","enrollment":120},{"nctId":"NCT01556815","phase":"PHASE2","title":"Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2012-05","conditions":"PHENYTOIN/SORAFENIB [VA Drug Interaction], Liver Neoplasms, Carcinoma, Hepatocellular","enrollment":40},{"nctId":"NCT01170104","phase":"PHASE2","title":"Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)","status":"UNKNOWN","sponsor":"Chung-Ang University","startDate":"2009-06","conditions":"Hepatocellular Carcinoma","enrollment":63},{"nctId":"NCT01324076","phase":"PHASE3","title":"Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery","status":"UNKNOWN","sponsor":"University College, London","startDate":"2010-11","conditions":"Liver Cancer","enrollment":412},{"nctId":"NCT00990860","phase":"PHASE2","title":"Study in Asia of the Combination of TACE With Sorafenib in HCC Patients","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2009-02","conditions":"Hepatocellular Carcinoma","enrollment":36},{"nctId":"NCT00768937","phase":"PHASE1, PHASE2","title":"Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2008-09","conditions":"Hepatocellular Carcinoma","enrollment":22},{"nctId":"NCT00478374","phase":"PHASE1","title":"Sorafenib With TACE to Treat Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"University of Bern","startDate":"2007-05","conditions":"Hepatocellular Carcinoma","enrollment":21},{"nctId":"NCT00999843","phase":"PHASE1, PHASE2","title":"Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2009-10","conditions":"Hepatocellular Carcinoma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TACE plus sorafenib","genericName":"TACE plus sorafenib","companyName":"Guangxi Medical University","companyId":"guangxi-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TACE (Transarterial Chemoembolization) combined with sorafenib is being studied as a treatment for Hepatocellular Carcinoma. Sorafenib is a small molecule serine/threonine-protein kinase RAF inhibitor.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}